The biotech news you missed from the weekend

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello from ASH! Writing this Readout from a press room at the annual hematology confab here in San Diego. Today’s edition is chockfull of Vertex content, plus some extras from ASH and elsewhere.

Vertex’s Joshua Boger is colorful

Joshua Boger, founder of Vertex Pharmaceuticals, still finds the company’s new sickle cell approval flabbergasting: “I would have lost a house in a bar bet if I had bet that Vertex would be the first company to bring a CRISPR drug to the world,” he told STAT. In a wide-ranging interview, Boger — who stepped down from his helm in 2017 after 28 years there — spoke about his work at Vertex, how he imagines biotech’s future, and what he thinks of Elon Musk. (Spoiler: He’s “extremely weird. He just doesn’t connect with people.”)

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In